Xiuning Le, MD, PhD

Xiuning Le, MD, PhD, is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center

Articles

Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD

March 24th 2025

Xiuning Le, MD, PhD, discusses the HARMONi-2 trial of ivonescimab in patients with advanced PD-L1–positive non–small cell lung cancer.

Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need

September 27th 2024

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.

Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC

September 10th 2024

Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.

Dr Le on the Efficacy of Osimertinib Plus Ramucirumab in EGFR-Mutant mNSCLC

October 28th 2023

Xiuning Le, MD, PhD, discusses findings from the interim analysis of the phase 2 RAMOSE trial in patients with TKI-naïve metastatic non–small cell lung cancer harboring EGFR mutations.

Dr Le on the Investigation of Osimertinib and Chemotherapy in Metastatic Lung Cancer

August 29th 2023

Xiuning Le, MD, PhD, discusses ongoing and future investigations with osimertinib and chemotherapy in patients with metastatic lung cancer.

Dr. Le on the Emergence of Antibody-Drug Conjugates in NSCLC

November 15th 2021

Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.

Dr. Le on Next Steps With Poziotinib in EGFR+ or HER2+ Exon 20 NSCLC

May 12th 2021

Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.

Dr. Le on the Safety of Twice-Daily Poziotinib in EGFR- or HER2 Exon 20–Positive NSCLC

April 10th 2021

Xiuning Le, MD, PhD, discusses the safety findings of the phase 2 ZENITH20-5 study with poziotinib in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Dr. Le on the Design of the VISION Trial in METex14-Mutant NSCLC

July 13th 2020

Xiuning Le, MD, PhD, discusses the design of the phase 2 VISION trial in MET exon 14 skipping—mutant non–small cell lung cancer.

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

June 9th 2020

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

x